Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

Stock Information for Windtree Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Windtree Therapeutics Inc.

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
Evofem Reports Fourth Consecutive Year of Net Sales Growth
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.